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MULTIPLE LASER PHOTOCOAGULATION TREATMENTS FOR THE 
MANAGEMENT OF DIABETIC MACULAR EDEMA 
Sadhna Vora, Curtis Hagedorn, Ron Adelman. 
Department of Ophthalmology, Yale University School of Medicine, New Haven, CT. 
 
The purpose of this study was to evaluate functional and funduscopic outcomes 
amongst patients receiving multiple treatments with macular laser photocoagulation for 
clinically significant diabetic macular edema.  A record review was conducted of patients 
who had multiple macular laser treatments for diabetic macular edema.  As part of 
routine follow-up for diabetic macular edema, visual acuity and funduscopic findings 
were assessed before a given laser treatment and at 6 months afterwards.  The study 
included 64 eyes from 41 patients. There was no statistically significant difference 
between the proportion of eyes that showed funduscopic improvement after treatment 1 
versus the proportion of eyes that improved after subsequent treatments.  For the first 
laser treatment, 44 of the 64 eyes (69%) showed funduscopic improvement in edema.   
35/64 (55%) of eyes showed improvement after the second treatment (p=0.15); 29/40 
(72.5%) eyes showed improvement after the third treatment (p=0.85); 15/18 (83.3%) eyes 
showed improvement after treatments ≥4 (p=0.36).  Similarly, in terms of visual acuity 
outcomes, there was no statistically significant difference between the proportion of eyes 
with preserved visual acuities after treatment 1 compared to repeat treatments.  This study 
found that the majority of eyes that receive re-treatment after initial laser therapy will 
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Diabetes is one of the leading causes of new blindness in the United States, giving 
rise to ocular microvascular complications such as diabetic retinopathy and diabetic 
macular edema.  Diabetic retinopathy is the proliferation of new blood vessels secondary 
to ischemia of the retina.  These new blood vessels are fragile, prone towards 
hyperpermeability and microaneurysm formation.  Leakage through these vessels causes 
a breakdown of the blood-retinal barrier with subsequent retinal thickening, a process that 
gives rise to diabetic macular edema.  Currently, tight glycemic control is the primary 
method of prevention of this long-term complication of diabetes.  Treatments for 




Diabetic retinopathy is one of the major causes of blindness in the U.S. in adults 
between the ages of 20 and 74, accounting for 8% of all cases of legal blindness and 12% 
of new diagnoses of blindness each year (1).  It has been shown that the duration of 
hyperglycemia, in addition to its extent, correlate with the severity of retinopathy (2).  
Clinically significant macular edema (CSME) is one of the complications of retinopathy 
that is potentially vision threatening in both type 1 and type 2 diabetics.  The incidence of 
CSME after 10 years of follow-up has been estimated at approximately 20% in Type I 
diabetics, 25% in Type II insulin dependent diabetics, and 13.9% in type II non-insulin 
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dependent diabetics (3).  Approximately half of patients with CSME will lose two or 
more lines of VA within 2 years (4).  
Diabetes-related blindness and visual impairment places significant demands on 
society, both monetarily and in terms of quality of life.  The cost of blindness to the 
federal government was found to be over $4 billion dollars in 1990 according to one 
study, with 97% of this expenditure devoted to working age adults (5).  This value 
accounts for both direct costs such as medical and personal care and the indirect cost of 
loss of labor.  More difficult to quantify is the effect on quality of life endured by patients 
with diabetes related vision problems (6).  In a recent study of 95 patients with diabetic 
retinopathy, 64 of 95 patients were willing to trade time of life in return for perfect vision 
in both eyes. The average patient expected to live for an additional 15.6 years and was 
willing to trade 3.3 of those remaining years in return for perfect vision (7).    
 
Pathophysiology  
   Diabetic retinopathy follows an orderly progression.  It begins as mild, 
nonproliferative changes that include increased vascular permeability.  It proceeds to 
moderate-to-severe nonproliferative retinopathy, characterized by microaneurysms and 
hemorrages.  This is the stage that macular edema is observed.  Finally, there is a 
progression to proliferative diabetic retinopathy, in which fragile new blood vessels 
proliferate.  Several studies have shown that hypertension and poor glycemic control 
contribute to the development of diabetic retinopathy and macular edema.  The biological 
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pathway of these changes is not fully understood, although several potential mechanisms 
have been proposed. 
Blood vessel walls do not need insulin to allow movement of glucose into cells.  
Therefore the high levels of glucose present in diabetes allow for a greater than normal 
influx of glucose into cells of capillaries.  The glucose then gets metabolized to sorbitol, a 
molecule too large to diffuse back out of the cells.  Osmotic flow of fluid into the cell 
results from the accumulation of sorbitol, ultimately leading to damage of endothelial 
cells and pericytes (8, 9).  The result is weakening of capillary walls and subsequent 
microaneurysm formation.  The thickening of the capillary basement membrane and 
increased deposition of extracellular matrix proteins interfere with the autoregulation of 
retinal blood flow, further contributing to microaneurysm formation.  Leakage from these 
microaneurysms causes macular edema.   
 In addition to the alteration of hemodynamics as a potential cause of diabetic 
macular edema, the increased leukocytosis that has been observed in diabetes has been 
implicated as another potential contributor.  Leukocytes adhere to vascular endothelium, 
altering blood flow.  In addition, superoxides and proteolytic enzymes generated by 
leukocytes have been proposed to damage vascular endothelium and limit capillary 
perfusion (10).  Supporting this theory is the observation that capillary leakage is 
associated with increased retinal white blood cells in diabetic laboratory rats (11). 
  There are two types of CSME, focal and diffuse, which differ both in their 
pathophysiology and appearance.  Focal lesions are the result of local microaneurysm 
formation.  Diffuse macular edema, by contrast, is caused by widespread vasodilation of 
the retinal vasculature as the result of the retinal nonperfusion in diabetes (11). 
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Diagnosis: 
CSME is defined by any one of the following: A) any retinal thickening at or within 
500 micrometers of the center of the macula B) hard exudates at or within 500 
micrometers of the center of the macula if associated with an adjacent area of 
thickening and/or C) a zone or zones of thickening one disc area in size or larger, any 
part of which is within one disc diameter of the center of the macula (12) (See Figure 
1).  It is important to note that vision loss is most threatened when CSME involves 
the center of the fovea. 
 
 
Figure 1: Clinically Significant Macular Edema: CSME is defined as at least 
one of the following: A) Retinal thickening within 500 micrometers of center of 
the macula B) hard exudates at or within 500 micrometers of the center associated 
with thickening and/ or C) a zone or zones of thickening one disc area in size or 
larger, any part of which is within one disc diameter of the center of the macula.           





Early detection is crucial for the management of CSME.  Current treatment 
strategies are effective at curbing the progression of vision loss but are not successful at 
restoring visual function that has already been compromised (13).  
 Currently, the standard means of detecting diabetic macular edema, and one of the 
methods that was employed in this study, is the presence or absence of macular 
thickening on fundoscopy.  This method is complementary with fundus photography, in 
which standard seven-field stereoscopic-color fundus photographs are obtained through a 
dilated pupil (14, 15).   
 Other methods of detection include fluoroscein angiography.  Patients are given 
an IV or oral load of fluorescein, which normally cannot pass through the blood-retina 
barrier.  However in certain disease states such as diabetic retinopathy, fluoroscein can 
traverse across hyperpermeable capillary walls, and can be visualized as “leakage”.  This 
method is more sensitive at detecting capillary leakage than funduscopy or fundus 
photography.  In addition, it also allows for detection of nonperfusion of the retina.  
Fluorescein angiography is especially useful when the decision to perform laser 
photocoagulation treatment has already been made, as it allows for determination of 
problem areas (11). 
 Finally, the newest technique for detection of CSME is ocular coherence 
tomography, or retinal thickness analysis.  This is a quantitative measure of CSME, 
unlike the other methods of detection.  This technique operates on similar principles as 
ultrasound, but uses light waves instead of sound waves to detect ocular structures, 
allowing for a much higher resolution of images (approximately 10 microns).  A standard 
200 watt 830 nm ray of light is split by an interferometer into a probe light beam and a 
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reference light beam.  The probe beam is pointed into the eye and the amount of time it 
takes to reflect back allows for a determination of the structural features of the retina.  
Multiple scans are taken and combined into a tomogram, which provides a 2-D 
representation of the back of the eye (16). 
 In 1998, Hee et al. designed a standard OCT protocol to measure diabetic macular 
edema.  In their protocol, six OCT scans are taken radially with fovea as center.  Then the 
retinal thickness is calculated at 600 macular locations.  These calculations allow for the 
production of a map of the topography of the eye (17).   
 The benefits of OCT include its high sensitivity for CSME, the ease of its use, its 
non-invasive nature, and the reproducibility of the results.  This last aspect allows for 
ease of monitoring the changes in a patient’s condition over time.  Furthermore, an 
important advantage over fluorescein angiography stems from the fact that substantial 




Control of the metabolic effects of diabetes has been shown to have a strongly 
positive influence on the microvascular complications of the disease.  The United 
Kingdom Prospective Diabetes Study (UKPDS) showed that glycemic control in type 2 
diabetics led to a 21% reduction in the risk of progression of retinopathy over roughly a 
decade (18).  Furthermore, treatment of hypertension in this patient population with either 
a beta blocker or an ACE inhibitor decreased the progression of diabetic retinopathy by 
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34% and was associated with a reduction in vision loss of close to 50% over the 7.5 year 
study period (19).   
Once CSME macular edema has been diagnosed, treatment options include laser 
photocoagulation treatments as well as medical therapies.  In more severe cases, surgical 
therapy is of benefit.  In such cases, vitreal traction is observed, owing to the 
development of a thin membrane over the retina.  Removal of the membrane reduces 
traction and has been associated with improvement in CSME.  Finally, newer 
pharmacological treatments include the use of PKC inhibitors and intravitreal 
triamcinolone injections.  The basis for the use of the former is evidence that the 
hyperglycemia of uncontrolled diabetes induces the synthesis of diacylglycerol, which in 
turn activates protein kinase C (PKC).  PKC B, in particular, induces retinal 
microvascular changes leading to increased permeability (20) and altered blood flow 
(21).  PKC inhibitors prevent this process, thereby curbing macular edema formation.   
The use of intravitreal triamcinolone injection is based on the reduction of 
inflammation caused by corticosteroids, as well as their observed downregulation of the 
production of VEGF (22) and protection of the blood-retinal barrier (23).  Notably, 
intraretinal injection of corticosteroids has been shown to be effective in patients for 
whom laser photocoagulation has failed (24).  However, the long term efficacy of 
intraretinal steroids has been called into question (25), suggesting that repeated injections 
might be necessary for the stabilization of visual acuity.   
Furthermore, triamcinolone injection can cause several important complications.  
Notably, intravitreal triamcinolone (IVT) has been associated with glaucoma in roughly 
35-50% of patients (24, 26-27).  Furthermore, Challa et al. found progression of cataracts 
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in 6 of 26 patients (23%) after 1 treatment with triamcinolone injection (28).  Similarly, 
Jonas et al. reported that 20% of 71 patients underwent cataract removal surgery within 6 
months of IVT (29).  Finally, endophthalmitis has been found to be a rare complication of 
this form of treatment, with a prevalence of 0.3% per injection and 0.9% per eye 
(including cases of noninfectious endophthalmitis). Excluding cases reported specifically 
as noninfectious endophthalmitis, the prevalence of endophthalmitis was 0.2% per 
injection and 0.5% per eye. (30)   
Given that the treatment method employed in this study was laser 
photocoagulation, we will discuss it in greater depth at this time.  The defining study in 
regards to the management of diabetic macular edema is the EDTRS study, which 
involved 3928 patients in multiple study centers from 1979 to 1989.  A significant result 
of the ETDRS was the definition of CSME, which was discussed above.  The results of 
the ETDRS demonstrated that focal/grid laser treatment for CSME reduced the risk of 
moderate visual loss by up to 50% over a three year period (12, 31, 32).  Supporting the 
success of laser photocoagulation treatments was the observation also that CSME 
resolved in up to 92% of cases treated by laser photocoagulation (33).  However, while 
many eyes showed promising results with laser treatment, a substantial cohort did not.  
According to ETDRS, 12% of treated eyes still lost at least 15 ETDRS at the three-year 
point.  Furthermore, almost 25% of eyes had thickening of the fovea at three years.   
The mechanism of action of macular laser for CSME is not clear.  In this 
treatment method, laser is applied directly to areas of leaky microaneurysms and in a grid 
pattern in areas of diffuse macular edema (34).    Early theories described acute closure of 
leaking microaneurysms by immediate “whitening” or “darkening” of microaneurysms 
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upon application of laser (12).  The likely mechanism for closure is likely 
thermocoagulation induced by laser treatment.  Subsequent clinicopathological study has 
demonstrated that these microaneuryms may close after clinically weak burns (35, 36), 
and closure may be delayed up to 12 weeks (37), suggesting an indirect mechanism.  This 
theory of an indirect mechanism has been further strengthened by the findings of success 
with laser using longer wavelengths (38-40).   
Resolution of macular edema after laser photocoagulation is a gradual process, 
occuring on a time scale of several months.  First, the fluid associated with CSME is 
absorbed across the blood retinal barrier, occurring between 3 and 6 months after laser 
treatment (11).  During this time period, lipoproteins dissolved in the edema fluid may 
precipitate out, forming hard exudates.  It is important to note that the diabetic 
retinopathy/ edema may appear to be worsening during this stage.  The lipoproteins are 
later digested by macrophages in the eye.  Only after the completion of this process does 











STATEMENT OF PURPOSE 
 
Several large multicenter studies have shown that laser photocoagulation 
treatment reduces the occurrence of macular edema in the majority of patients and 
inhibits progression of vision loss in roughly half of patients.  However, there is limited 
information available regarding efficacy of macular laser retreatments for CSME in those 
patients for whom the first treatment did not lead to lasting resolution of edema.  This 
question is especially important to answer given the growing popularity and success of 
alternative treatments for CSME including intravitreal triamcinolone acetonide, PKC 
inhibitors and vitrectomy surgery (24, 29, 41-46).  Given these alternatives to laser 
photocoagulation, which currently remains the gold standard, it is valuable to assess the 
efficacy of repeated macular laser treatments. 
 Our study had two purposes: the first was to examine both visual and funduscopic 
outcomes in patients receiving two, three, or four or more macular laser treatments.  The 
second goal of this study was to determine whether success or failure after early 
treatments predicts in any way the success of future laser photocoagulation treatment.  In 
particular, we wished to examine whether complete resolution after a given treatment is 
associated with a higher rate of success on retreatment (in which case retreatment is given 
due to a recurrence of edema vs. failure of treatment).  In addition, we sought to 
determine whether there existed a specific number of treatment failures beyond which it 
became unlikely that retreatment would be successful: in other words, if a patient had 
experienced poor outcomes after a specific number of consecutive macular 
photocoagulation treatments, it would not be worthwhile to offer re-treatment with laser 
photocoagulation. 
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PATIENTS AND METHODS 
 
Patients who were evaluated at the Yale Eye Center between January, 1988 and 
May, 2004 for multiple treatments with laser photocoagulation for diabetic macular 
edema were included in this retrospective record review.   Data extracted from the 
medical records included patients’ age, sex, type of laser treatment, visual acuity before 
treatment and at follow-up, retinopathy changes, and treatment complications.  
Information about metabolic control and blood pressure were not uniformly available for 
all of the patients enrolled in this study.   
Patients were included based on the criteria for clinically significant macular 
edema according to the ETDRS.  Specifically, the exclusion criteria for the current study 
included treatment with panretinal photocoagulation, retinal detachment or retinal 
trauma, prior laser photocoagulation treatment at another institution, visual acuity worse 
than 20/200 prior to any laser photocoagulation treatments, or concurrent alternate 
treatment for diabetic macular edema such as triamcinolone acetonide injections or 
protein kinase C inhibitor before or during the period of treatment.  Furthermore, to be 
included in the present study, patients must have received at least 2 laser 
photocoagulation treatments and had follow-up evaluations for at least 6 months 
following their most recent photocoagulation treatment.   
Patients in the study received multiple focal/grid laser photocoagulation 
treatments for diabetic macular edema based on clinical evaluation of their persistent or 




As part of routine treatment for diabetic macular edema, all patients underwent 
ophthalmologic evaluation prior to each treatment and at 3 months, 6 months, and 1 year 
as clinically indicated.  In addition, retinal evaluation included stereoscopic fundus 
examination using the 78 or 90 diopter lens or the contact lens evaluation.  Macular 
edema was described after a given laser treatment as “resolved,” “improved,” “stable”, or 
“worsened” relative to the pre-treatment exam.  In addition, fluorescein angiographs were 
obtained as clinically indicated.  
 Laser photocoagulation was conducted in a focal/grid pattern under topical 
anesthesia.  Focal laser was applied to leaking microaneurysms and a grid pattern was 
used in areas of diffuse edema as described by the ETDRS (47).  A macular contact lens 
and an argon laser were used.  Laser applications were given with spot sizes of 50-100 
microns for 0.05-0.1 seconds.  The power of the laser was adjusted based on thickness of 
the retina and take of the laser.     
 The visual acuities and funduscopic findings at the 6 month check-up were used 
in the present analysis.  Fundus findings were determined by comparing stereoscopic 
funduscopic photos, fluorescein angiographs, and the examining physician notes in the 
chart.   
In the current study a “positive funduscopic” outcome is defined either as 
complete resolution or improvement of diabetic macular edema.  “Negative funduscopic” 
outcomes are identified as either stability or worsening of edema.  By contrast, a 
“positive visual acuity outcome” is defined as either improvement or stability of visual 
acuity as measured by the Snellen logarithmic scale.  “Negative visual acuity outcomes” 
are defined as worsening of visual acuity.   
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Comparisons of treatment outcomes were done with change in each eye using 
student t tests for visual acuity and Chi-square or Fisher exact tests for funduscopic 
changes, as appropriate.  This study was approved by the Human Investigations 








































The study included 64 eyes of 41 patients.  (See Table 1 for the number of 
patients and number of eyes receiving a given number of laser treatments.).   
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Table 1: Number of Patients and Eyes Receiving a Given Number of 
Treatments.  To be included in this study, patients must have had at least 2 laser 
photocoagulation treatments for diabetic macular edema.   
 
The average visual acuity eyes before treatment was 0.27 logMAR or 0.54 by 
decimal notation (approximately 20/40 according to Snellen visual acuity notation). 
 
 
Comparison of Funduscopic Findings for each Treatment 
Following the first laser treatment, 44 of the 64 eyes (69%) showed funduscopic 
improvement in edema, 13 (20.3%) were stable, and 7 (10.9%) showed worsening.  The 
proportion of eyes that showed reduced amounts of macular edema after repeated laser 
treatment was not significantly different from the results observed after this first laser 
treatment.  Following the second treatment, 35 of 64 (55%) eyes improved, 20 (31.2%) 
were stable, and 9 (14.1%) worsened (p value for positive outcome of treatment 2 vs. 
treatment 1 = 0.15).  For the third treatment 29 of 40 eyes (72.5%) improved, 8 (19.5%) 
were stable, and 3 (7.3%) worsened (p value for treatment 3 vs. treatment 1= 0.85).  For  
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≥ 4 treatments, 15 of 18 (83.3%) eyes improved, 1 (5.6%) was stable, and 2 (11.1%) 
worsened (p value for treatment 4-7 vs.1 = 0.36).  (See Figure 2 for a summary of the 




























Stability or Worsening or
Edema
 
Figure 2: Percentage of Eyes with Positive and Negative Funduscopic 
Findings for each Treatment.  In this figure, positive outcomes are defined as 
reduction in the amount of macular edema 6 months after treatment.  Negative 
outcomes are defined as stability or worsening of macular edema 6 months after 
treatment.  There is no significant difference between the success rate of the first 
treatment and that of subsequent treatments. 
 
Furthermore, the proportion of eyes achieving complete resolution after any given 
repeat treatment was not significantly different from the corresponding proportion after 
the first treatment.  17 of 64 eyes (26.6%) had complete resolution of diabetic macular 
edema after the first laser treatment.  14 of 64 eyes (21.9%) of eyes had resolution of 
macular edema after the second laser treatment (p=0.72 for treatment 2 vs. treatment 1).  
Macular edema in 16 of 40 eyes (40%) resolved after the third laser treatment (p=0.22 for 
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treatment 3 vs. treatment 1) and in 7 of 18 eyes (38.9%) after the fourth laser treatment 
(p= 0.47 for treatments ≥4 vs. treatment 1).  
 
 
Funduscopic Outcomes of Early Treatments as Predictors of Outcome after 
Repeated Laser Treatment: 
 
 The next goal of the study was to determine whether those patients that had the 
best results after a given treatment, i.e. complete resolution of edema, had better 
outcomes upon subsequent treatment than the remainder of patients.  To address this 
question, we conducted analyses to see whether resolution of edema after a given laser 
treatment predisposed the patient to a better outcome on the subsequent treatment as 
compared to patients receiving repeat treatments for lack of resolution of macular edema.  
Retreatment in patients who had achieved resolution of edema after a given treatment 
was conducted due to recurrence of edema rather than treatment failure. 
Based on inclusion criteria, all 44 patients that showed improvement after the first 
laser treatment required repeat laser treatment, regardless of whether laser treatment had 
yielded temporary resolution or not.  The eyes that had complete resolution of edema 
after the first treatment had a significantly higher success rate after the second treatment 
than the remainder of eyes.  Of the 17 eyes that had resolution of macular edema after the 
first treatment and experienced recurrence, 76.5% (n=13) had positive funduscopic 
outcomes after the second treatment versus 46.8% (22 of 47) of those patients that had 
not achieved complete resolution after treatment 1 (p=0.048).   
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Eyes that achieved complete resolution of edema after treatments 2 or 3 showed a 
trend, albeit not a statistically significant difference, towards better outcomes upon 
retreatment than their counterparts who had not achieved complete resolution.  Of the 40 
eyes that needed a third treatment, 9 had achieved complete resolution of edema after 
treatment 2; 31 eyes had either worsened or not shown complete resolution after 
treatment 2.  8 of the 9 eyes (88.9%) in the former group had positive outcomes after the 
third treatment versus 21 of the remaining 31 eyes (67.7%) (p= 0.40.)   
Of the 18 eyes that needed a fourth treatment, 6 had achieved complete 
resolution of edema after treatment 3.  All 6 of these eyes (100%) had positive 
outcomes after the fourth treatment vs. 66% (8/12) of the remaining eyes 
(p=0.25) in treatment 4.   
Having thus examined whether those patients with the best outcomes after a given 
treatment fared better on subsequent treatment, we studied whether patients with poor 
funduscopic outcomes were predisposed towards failures of future treatment.  In 
particular, we wished to determine whether there existed a specific number of failures 
after which the probability of future success became very unlikely.  To address this goal, 
we examined whether consecutive failures of treatment were associated with significantly 
lower rates of success after the next treatment.   
We found that eyes that had negative funduscopic outcomes after the first 
treatment had a similar rate of success on second treatment as eyes that had experienced 
positive outcomes (resolution or improvement of edema) after the first treatment.  Of the 
20 eyes that worsened after the first treatment, 50% had positive results after the second 
treatment.  By comparison, of the 44 eyes that had positive results after the first 
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treatment, 56.8% (25 of 44) resolved or improved after the second treatment.  The 
difference in success rates upon second treatment between these two groups was 
therefore not statistically significant (p=0.81).  Thus a poor result after treatment 1 did 
not predict a poor result upon treatment 2. 
We further observed that two consecutive funduscopic treatment failures resulted 
in a difference in success rates on the third treatment that approached statistical 
significance.  Of the 7 eyes receiving a third treatment after failures of both of the first 
two treatments, 3 had positive funduscopic outcomes after treatment 3 (42.9%).  In 
comparison, 26 of 33 of the remainder of eyes requiring a third treatment achieved a 
positive outcome on this treatment (79%) (p=0.075).   
Finally, we found that eyes with 3 consecutive treatment failures were unlikely, 
by our analysis, to achieve positive outcomes on the fourth treatment.  All 3 of the eyes 
that had negative outcomes in treatments 1 through 3 also had negative outcomes in the 
fourth treatment.  By contrast, 14 of the remaining 15 eyes needing a fourth treatment 
(93.3%) had positive outcomes (p=0.0049).  The difference in outcome on the fourth 
treatment between eyes that had experienced 3 consecutive failures vs. the remainder of 






Comparison of Visual Acuity Outcomes for each Treatment 
 
 24
After the first laser treatment, 21 of the 64 patients (32.8%) showed an 
improvement in best corrected visual acuity as documented by the Snellen chart, 22 
(34.4%) were stable, and 21 (32.8%) had worsened visual acuity.  Note that while the 
success rate (improvement or stabilization) amongst patients in the present analysis was 
roughly 67% compared to the 50% observed in the ETDRS trial, the follow-up interval 
we used for this calculation was 6 months, compared to 3 years in the ETDRS trial.   
The proportion of eyes with stable or improved visual acuity vs. worsened visual 
acuity on subsequent treatment did not show a statistically significant difference from the 
first treatment.  Following treatment 2, 14 eyes (21.9%) improved, 29 eyes (45.3%) were 
stable, and 21 eyes (32.8%) worsened.  After treatment 3, 15 eyes (37.5%) improved, 14 
eyes (35%) were stable, and 11 eyes (27.5%) worsened.  Finally, after treatments ≥4, 4 
eyes improved (22.2%), 9 eyes (50%) were stable, and 5 eyes (27.8%) worsened.  Thus 
visual acuity was maintained in 67.2% of patients after treatment 2, 72.5% of patients 
after treatment 3, and 72.2% of patients after treatments ≥4.  The p values for these 
success rates vs. that of treatment 1 were as follows: treatment 2 vs. treatment 1, p= 1.0; 
treatment 3 vs. treatment 1, p=0.73; treatment ≥4 vs. treatment 1, p=1.0. (See figure 3 for 






























Figure 3: Percentage of Eyes with Positive and Negative Visual Acuity 
Outcomes for each Treatment.  In this figure, positive outcomes are defined as 
stability or improvement of visual acuity at the 6 month follow-up after treatment.  
Negative outcomes are defined as worsening of visual acuity at 6 months after a 
given treatment.  There is no significant difference between the success rate of the 
first treatment and that of subsequent treatments. 
 
 
Visual Acuity Outcomes of Early Treatments as Predictors of Outcome after 
Repeated Laser Treatment: 
 
As with funduscopic outcomes, we studied whether poor visual acuity outcomes 
after a given treatment predisposed patients for poor visual outcomes on subsequent 
treatments.  Furthermore, we questioned whether there existed a specific number of 
treatment failures after which subsequent treatment was unlikely to be successful at 
maintaining visual acuity. 
Worsening of visual acuity after the first treatment (failure of treatment by visual 
acuity criteria) was not associated with a lower rate of positive visual acuity outcomes in 
the next treatment.  Of the 43 eyes that had improved or stable visual acuities (positive 
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outcome) after the first laser treatment, 29 (67.4%) showed positive visual acuity 
outcomes after treatment 2.  In comparison, 66.7% of the 21 eyes with negative outcomes 
after the first laser treatment had positive outcomes after the second treatment (p=0.82).  
Thus visual acuity outcome after the first treatment did not predict success or failure upon 
retreatment. 
Of the 40 eyes needing a third treatment, 7 had experienced negative visual acuity 
outcomes after both treatments 1 and 2.  On the other hand, 33 had experienced a positive 
visual acuity outcome after at least 1 of the prior two treatments.  Of the former group, all 
7 achieved a positive outcome on the third treatment (100%).  This is in comparison with 
a 66.7% (22/33) rate of positive outcomes in the third treatment amongst the remainder of 
eyes (p=0.16).   Thus a poor visual acuity outcome after both treatments 1 and 2 was not 

























The use of multiple focal/ grid laser treatments for CSME poses an interesting 
clinical question, particularly with the recent introduction of intraocular steroid injection 
as a possible alternative treatment to laser photocoagulation.   
We found that additional macular laser treatments for diabetic macular edema are 
effective in improving retinal thickness.  This study supports the results of previous 
studies, whose conclusions suggest that repeat laser treatments for diabetic macular 
edema may be beneficial.  For example, Yi et al. found that in a sample of 136 eyes that 
did not have resolution of CSME after the first laser treatment, resolution occurred upon 
subsequent treatment in 116 (85.6%) eyes (28).   
According to our study, repeat laser treatments were also successful in 
maintaining visual acuity in the majority of patients with diabetic macular edema.  This 
observation applied regardless of treatment number.   
This study suggests that patients who had a recurrence of edema after full 
resolution with laser treatment may have a higher chance of a positive funduscopic 
outcome with retreatment than patients who had never achieved full resolution.  For 
example, of patients undergoing a second treatment, close to 80% of those obtaining 
retreatment for recurrence of edema had positive funduscopic outcomes, versus roughly 
50% of those who had incomplete responses to the first treatment (p=0.048).  In the 
present analysis, we observed a trend suggesting that patients achieving full resolution of 
macular edema on any given treatment were more likely to have successful repeat 
treatments than their counterparts who had never achieved full resolution; however, a 
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statistically significant difference between these two groups was only observed on the 
first retreatment, i.e. treatment 2.  It is important to note that the number of patients 
involved in treatments 3 and higher decreased, making a statistical difference between 
these two groups more difficult to detect.  Furthermore, our results do not imply that re-
treatment should not be attempted in those patients who failed to achieve complete 
resolution on early treatments, as a significant proportion of these patients have success 
on retreatment.   
Our study further suggests that there may be a limit to how many times treatment 
should be reattempted if it has never produced positive results.  The results imply that for 
patients with up to 2 negative outcomes on consecutive treatments, there is still a high 
likelihood of positive visual acuity outcomes from further treatment: in our study 100% 
of the 7 eyes receiving a third treatment after two consecutive failures to maintain visual 
acuity had successful visual acuity outcomes on the third attempt.  Furthermore, just over 
40% of the patients in our study who had funduscopic failures on their first 2 treatments 
had an improvement in their fundus exam after their third treatment.   
However, if a patient fails three consecutive treatments, our study provides no 
evidence that further laser treatment would be beneficial.  In terms of funduscopic 
findings, all three of the patients who had failed treatments 1-3 also failed subsequent 
treatment.  This result is in comparison to a 93% success rate amongst the remainder of 
eyes (p= 0.0049) on the fourth treatment.  .   
Our study was started before the availability of optical coherence tomography at 
our center.  Studies using ocular coherence tomography may prove beneficial because 
OCT would allow a quantitization of changes in macular edema. While this tool would 
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add important information to the analysis of the efficacy of repeated macular laser 
treatment, it is also worth noting that recent studies have shown that ocular coherence 
tomography corroborates findings on funduscopic exam (48).  This observation suggests 
that the results of studies using OCT would support the current findings.  Another 
limitation of the present study is that it is a retrospective case series; a prospective 
multicenter randomized clinical trial is needed to evaluate repeat macular laser treatments 
for persistent and recurrent macular edema. 
The results of this study suggest that repeated laser photocoagulation treatments 
for CSME are effective and that the majority of eyes receiving repeat treatments will 
respond with improvement in macular edema and stability or improvement of visual 
acuity.   However, given the existence of viable alternatives, it is important for treatments 
>3, to consider whether the patient has ever responded positively to prior treatments.  The 
results of our study do not provide support for continuing focal/grid laser treatments for 
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